Cystic Fibrosis Ireland welcomes the landmark breakthrough on CF drugs Orkambi and Symkevi in Scotland announced today
CF Ireland further strongly supports the extension of these 2 important CF drug therapies to patients in England, Wales and Northern Ireland who continue to be denied these drugs.
In a new five-year agreement hundreds of patients who have been waiting, in many cases up to four years, for access to the precision medicines Orkambi and Symkevi for people with Cystic Fibrosis, will now have access to drugs that have been shown to significantly retard the decline in lung function, reduce hospital admissions and to dramatically reduce the need for some other expensive CF drugs, in particular powerful/usually hospital administered antibiotics.
Philip Watt CEO of CFI stated;
‘We congratulate the UK Cystic Fibrosis Trust and their members for all their campaigning to ensure access to Orkambi and Symkevi over the last 4 years. We are sure that the Scottish health authorities decision to make this deal with Vertex will have been in part informed by the very positive impact of these two drug therapies in Ireland (introduced in April 2017) and other countries including Sweden, Belgium, the United States of America, Netherlands and Australia. We would add our voice to that of the CF Trust in the UK today and urge that the whole of the Great Britain and Northern Ireland would now follow suit, as patients in these regions are still being denied access to these crucial and proven precision CF drugs. The fact that so many other countries, including Scotland, have now approved Orkambi and Symkevi also shows that there is growing worldwide awareness of the importance and impact of these drugs. Further CFI is very excited about even another drug CF therapy that is in an advanced clinical stage and will likely become available in Ireland in about 2 years time’.